Kuwait

Reimbursed Care Access

Kuwait enforces a strict new unified narcotics and psychotropic law (Decree‑Law No. 159/2025) that tightly controls import, prescribing, dispensing and research of narcotics and psychotropic substances; most classic psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, ibogaine, ayahuasca, mescaline, 2C‑X) have no authorised medical access outside tightly‑regulated research or are effectively prohibited for non‑medical use. Ketamine remains an established anesthetic and emergency medicine in Kuwaiti clinical practice but is subject to stringent prescription, recordkeeping and supply‑chain controls; there is no clear public record of esketamine (Spravato®) national approval or public reimbursement as of Feb 20, 2026. [https://www.meysan.com/kuwaits-new-narcotics-law-comply-comply-comply/|Meysan legal note on Kuwait Narcotics Law] [https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02|WHO Model List of Essential Medicines (2023)].